2016 Form 10-K Financial Statement
#000114420418013470 Filed on March 08, 2018
Income Statement
| Concept | 2016 | 2015 Q4 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $2.830M | $570.0K |
| YoY Change | -21.17% | -44.66% |
| % of Gross Profit | ||
| Research & Development | $2.250M | $830.0K |
| YoY Change | -54.54% | -49.39% |
| % of Gross Profit | ||
| Depreciation & Amortization | $77.00K | $20.00K |
| YoY Change | -11.49% | -33.33% |
| % of Gross Profit | ||
| Operating Expenses | $2.250M | $1.400M |
| YoY Change | -54.54% | -47.57% |
| Operating Profit | -$5.083M | |
| YoY Change | -40.45% | |
| Interest Expense | ||
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | $100.0K | $10.00K |
| YoY Change | 100.0% | -116.67% |
| Pretax Income | -$1.451M | -$1.380M |
| YoY Change | -48.94% | -49.45% |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$4.982M | -$1.380M |
| YoY Change | -41.31% | -49.45% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$266.9K | -$74.35K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 18.50M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2016 | 2015 Q4 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $9.990M | $15.96M |
| YoY Change | -37.41% | 86.89% |
| Cash & Equivalents | $550.0K | $428.0K |
| Short-Term Investments | $9.440M | $15.53M |
| Other Short-Term Assets | $150.0K | $70.00K |
| YoY Change | 114.29% | 133.33% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $310.0K | $760.0K |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $10.44M | $16.79M |
| YoY Change | -37.82% | 74.91% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $300.0K | $271.0K |
| YoY Change | 11.11% | -13.42% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $30.00K | $292.0K |
| YoY Change | 50.0% | -12.31% |
| Total Long-Term Assets | $330.0K | $292.0K |
| YoY Change | 13.79% | -6.71% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $10.44M | $16.79M |
| Total Long-Term Assets | $330.0K | $292.0K |
| Total Assets | $10.77M | $17.08M |
| YoY Change | -36.94% | 72.33% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $350.0K | $1.169M |
| YoY Change | -70.09% | -24.19% |
| Accrued Expenses | $150.0K | $1.500M |
| YoY Change | -90.0% | 11.36% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $0.00 | |
| YoY Change | ||
| Total Short-Term Liabilities | $860.0K | $2.952M |
| YoY Change | -70.85% | -5.17% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $0.00 | |
| YoY Change | -100.0% | |
| Total Long-Term Liabilities | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $860.0K | $2.952M |
| Total Long-Term Liabilities | $0.00 | $0.00 |
| Total Liabilities | $860.0K | $2.952M |
| YoY Change | -70.85% | -8.78% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$70.14M | |
| YoY Change | 13.77% | |
| Common Stock | $84.27M | |
| YoY Change | 23.33% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $9.900M | $14.13M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $10.77M | $17.08M |
| YoY Change | -36.94% | 72.33% |
Cashflow Statement
| Concept | 2016 | 2015 Q4 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$4.982M | -$1.380M |
| YoY Change | -41.31% | -49.45% |
| Depreciation, Depletion And Amortization | $77.00K | $20.00K |
| YoY Change | -11.49% | -33.33% |
| Cash From Operating Activities | -$5.858M | -$1.290M |
| YoY Change | -20.94% | -35.82% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $103.0K | -$20.00K |
| YoY Change | 128.89% | -71.43% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $6.080M | $910.0K |
| YoY Change | -154.09% | -133.83% |
| Cash From Investing Activities | $5.977M | $900.0K |
| YoY Change | -152.99% | -132.61% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | $0.00 | 110.0K |
| YoY Change | -100.0% | 120.0% |
| NET CHANGE | ||
| Cash From Operating Activities | -$5.858M | -1.290M |
| Cash From Investing Activities | $5.977M | 900.0K |
| Cash From Financing Activities | $0.00 | 110.0K |
| Net Change In Cash | $119.0K | -280.0K |
| YoY Change | -103.12% | -94.07% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$5.858M | -$1.290M |
| Capital Expenditures | $103.0K | -$20.00K |
| Free Cash Flow | -$5.961M | -$1.270M |
| YoY Change | -20.04% | -34.54% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-4982000 | USD |
| CY2017 | us-gaap |
Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
|
62000 | USD |
| CY2017 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
554000 | USD |
| CY2017 | us-gaap |
Depreciation
Depreciation
|
85000 | USD |
| CY2016 | us-gaap |
Depreciation
Depreciation
|
77000 | USD |
| CY2016 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-1264000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
1079000 | USD |
| CY2016 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-824000 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2364000 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-5858000 | USD |
| CY2017 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
554000 | USD |
| CY2016 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
635000 | USD |
| CY2017 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
62000 | USD |
| CY2016 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
121000 | USD |
| CY2017 | bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
2792000 | USD |
| CY2016 | bcli |
Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
|
-379000 | USD |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
180000 | USD |
| CY2016 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
103000 | USD |
| CY2017Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
5901533 | shares |
| CY2017 | bcli |
Research And Development Cost
ResearchAndDevelopmentCost
|
6795000 | USD |
| CY2017Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
51107000 | USD |
| CY2016Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
39967000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
14090000 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
13333000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
14090000 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
13333000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-2532000 | USD |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-1451000 | USD |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-2420000 | USD |
| CY2017 | us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
-4170000 | USD |
| CY2016 | us-gaap |
Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
|
-6084000 | USD |
| CY2017 | bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
4000 | USD |
| CY2016 | bcli |
Investment In Lease Deposit
InvestmentInLeaseDeposit
|
4000 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
3986000 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
5977000 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
314000 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | USD |
| CY2017 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1936000 | USD |
| CY2016 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
119000 | USD |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
428000 | USD |
| CY2017 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
314000 | USD |
| CY2016 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | USD |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
800000000 | shares |
| CY2015Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
|
0.0833 | pure |
| CY2017 | bcli |
Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus
|
0.05 | pure |
| CY2017 | bcli |
Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
|
0.03 | pure |
| CY2017Q4 | us-gaap |
Grants Receivable Current
GrantsReceivableCurrent
|
574000 | USD |
| CY2016Q4 | us-gaap |
Grants Receivable Current
GrantsReceivableCurrent
|
154000 | USD |
| CY2017Q4 | us-gaap |
Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
|
98000 | USD |
| CY2016Q4 | us-gaap |
Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
|
152000 | USD |
| CY2017 | bcli |
Amounts Of Grants Received
AmountsOfGrantsReceived
|
988000 | USD |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
616000 | USD |
| CY2016 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
756000 | USD |
| CY2016 | bcli |
Research And Development Cost
ResearchAndDevelopmentCost
|
3435000 | USD |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-3531000 | USD |
| CY2017Q4 | bcli |
Deferred Grant Income
DeferredGrantIncome
|
2625000 | USD |
| CY2016Q4 | bcli |
Deferred Grant Income
DeferredGrantIncome
|
0 | USD |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00005 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00005 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18976169 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18976169 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18687987 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18687987 | shares |
| CY2017 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
209000 | USD |
| CY2017 | bcli |
Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
|
105000 | USD |
| CY2017 | bcli |
Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
|
2625000 | USD |
| CY2016 | bcli |
Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
|
0 | USD |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1853000 | USD |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1673000 | USD |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1461000 | USD |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1376000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
448000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
206000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
199000 | USD |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
43000 | USD |
| CY2017 | bcli |
Lease Agreement Termination Description
LeaseAgreementTerminationDescription
|
option to terminate the agreement with 4 month pre-notice, before December 31, 2019 | |
| CY2017 | bcli |
Lease Agreement Entry Date
LeaseAgreementEntryDate
|
October 2017 | |
| CY2017 | us-gaap |
Maturity Of Time Deposits
MaturityOfTimeDeposits
|
P5M | |
| CY2016 | us-gaap |
Maturity Of Time Deposits
MaturityOfTimeDeposits
|
P5M | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-4952000 | USD |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
940954 | shares |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
874841 | shares |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y7M2D | |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y4M17D | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
811824 | shares |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
839509 | shares |
| CY2007Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
3.00 | |
| CY2017 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
46600000 | USD |
| CY2017 | bcli |
Grants Underlying Basis
GrantsUnderlyingBasis
|
The grant is linked to the exchange rate of the dollar and bears interest of Libor per annum. | |
| CY2017 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -27.75pt; MARGIN: 0in 0in 0pt 112.8pt" align="justify"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>B.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><b> <font style="FONT-SIZE: 10pt">Use of estimates:</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2017 | bcli |
Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
|
P15Y | |
| CY2017Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1103000 | USD |
| CY2017Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
1378000 | USD |
